Characterization of focal hepatic lesions with contrast-enhanced C-cube gray scale ultrasonography

Table 1 Hemodynamics of focal hepatic lesions on contrast-enhanced C-cube gray scale ultrasonography

Types of lesion	No. of lesions	Injection-enhancement delaytime (mean ± SD) (s)			Enhancement duration (mean ± SD) (s)
		Liver	Lesion	P Value	Lesion	P Value
Primary liver cancer	29	33 ± 10	23 ± 6	< 0.05	69 ± 33b	—
Metastasis	4	26 ± 7	26 ± 11	< 0.05	59 ± 22c	—
Hemangioma	8	36 ± 8	48 ± 12a	—	221 ± 47	< 0.05
Focal nodular hyperplasia	12	29 ± 9	20 ± 6	< 0.05	196 ± 96	< 0.05
Angiomyolipoma	3	37 ± 12	26 ± 6	< 0.05	177 ± 90	< 0.05

^aThe injection-enhancement delay time after administration of Levovist in hemangioma was significantly longer than that in other types of lesions (P < 0.05).

^bThe enhancement duration in primary liver cancer was significantly shorter than that in benign lesions (P < 0.05).

^cThe enhancement duration in metastasis was significantly shorter than that in benign lesions (P < 0.05).

Table 2 Enhancement patterns of focal liver lesions in the arterial phase on contrast-enhanced C-cube gray scale ultrasonography

Enhancement patterns	Peripheral	Homogenous	Mosaic	Negative	Total
Primary liver cancer	1	16	12	0	29
Metastasis	2	0	2	0	4
Hemangioma	7	0	1	0	8
Focal nodular hyperplasia	0	12	0	0	12
Angiomyolipoma	0	1	2	0	3
Inflammatory pseudotumor	0	0	0	2	2
Total	10	29	17	2	58

Note: Values are number of lesions.